You are viewing: UK AI in Precision Medicine Market analysis

The UK AI in Precision Medicine Market was valued at $3.45 Million in 2024 and projected to reach to $17.54 Million by 2029, representing a compound annual growth rate of 24.2%. The UK AI in Precision Medicine market is positioned for substantial expansion, driven by NHS digitalization initiatives, increasing genomic sequencing adoption, and growing demand for personalized treatment approaches.

UK AI in Precision Medicine Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

UK AI in Precision Medicine Market Trends and Insights

  • The UK's advanced healthcare infrastructure, strong regulatory framework, and investment in digital health technologies are driving adoption of AI-powered precision medicine solutions across clinical settings.
  • The UK's National Health Service (NHS) and private healthcare providers are increasingly integrating AI algorithms for personalized treatment planning, genomic analysis, and patient risk stratification. The UK market is characterized by significant innovation in machine learning applications for drug discovery, diagnostic imaging, and treatment optimization.
  • Between 2024 and 2029, the UK is expected to see accelerated deployment of AI tools in oncology, cardiology, and rare disease management.
  • The UK's position as a life sciences hub, combined with growing partnerships between academic institutions and healthcare technology companies, positions the country as a key growth market within Europe for AI-driven precision medicine solutions..

Key Market Statistics

  • CAGR (2024-2029) 24.2% CAGR
  • Market Size, 2024 ~USD 3.45 Million
  • Forecast, 2029 ~USD 17.54 Million
  • Country UK

UK AI in Precision Medicine Market Overview

NHS Digital Transformation :

The UK National Health Service's commitment to digital health integration is accelerating AI adoption in precision medicine, with NHS trusts increasingly implementing AI-driven diagnostic and treatment planning tools across major hospital networks.

Regulatory Leadership :

The UK's robust regulatory framework, including MHRA oversight and NICE guidance, provides clear pathways for AI precision medicine solutions, fostering innovation while maintaining patient safety standards that attract global investment.

Strong Market Growth Trajectory :

With a CAGR of 24.2%, the UK market is expanding from $3.45 million in 2024 to $17.54 million by 2029, significantly outpacing broader healthcare IT adoption rates and reflecting strong institutional and private sector investment.

Academic and Research Excellence :

Leading UK universities and research institutions are driving precision medicine innovation through AI partnerships, creating a robust ecosystem that supports clinical validation and real-world evidence generation for AI-powered solutions.

UK AI in Precision Medicine Market Dynamics

  • Healthcare providers are investing in AI infrastructure to improve diagnostic accuracy, reduce treatment timelines, and optimize patient outcomes across oncology, cardiology, and rare disease management.
  • The UK's regulatory environment and emphasis on evidence-based medicine create favorable conditions for solution deployment.
  • By 2029, market growth will be supported by expanded NHS funding for digital health, increased collaboration between public and private healthcare sectors, and rising patient expectations for personalized care.
  • Challenges including data interoperability, workforce training, and implementation costs will be addressed through government initiatives and industry partnerships, ensuring sustained market momentum..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Danaher Corporation

    Analytical And Scientific Instrumentation

    Top Technologies
    • Environmental Testing
    • Gas Chromatography
    • Polymerase Chain Reaction (PCR)
    • Automated Liquid Handling Systems
    • Flow Cytometry
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • Shimadzu Corporation
    • Merck KGaA

      Healthcare Analytics

      Top Technologies
      • Machine Learning
      • Natural Language Processing (NLP)
      • Blood Pressure Monitors
      • Computed Tomography (CT)
      • Magnetic Resonance Imaging (MRI)
      Top Companies
      • Oracle Corporation
      • PHILIPS HEALTHCARE
      • Siemens healthineers
      • Zensar Technologies Limited
      • EPIC SYSTEMS CORPORATION

        Key Takeaways

        • The UK AI in Precision Medicine market will grow from $3.45M (2024) to $17.54M (2029), representing a 24.2% CAGR.
        • The UK's NHS digitalization initiatives and regulatory support are accelerating AI adoption in precision medicine across the country.
        • The UK market is driven by increasing demand for personalized treatment approaches in oncology, cardiology, and genomic medicine.
        • The UK's strong life sciences ecosystem and academic-industry partnerships position it as a leading European hub for AI precision medicine innovation.

        AI in Precision Medicine Market Report Scope

        Report Metric Details
        Base Year 2024
        Fastest Growing Segment IMAGE ANALYSIS (Tool)
        Forecast Period 2024-2029
        Growth Rate CAGR of 30.7% from 2024 to 2029
        Largest Segment SOFTWARE (Component)
        Market Size Base Year (Billions) ~USD 0.79 (2024)
        Revenue Forecast (Billions) ~USD 3.92 (2029)
        Segments Covered Application, Type, Therapeutic Area, Component, Tool, Deployment, End User, Deployment 2022-2030

        UK AI in Precision Medicine Market Report Segmentation

        8 segment dimensions are covered across the global market.

        By Application

        • Clinical Development
        • De Novo Drug Design
        • Diagnostic & Screening
        • Diagnostics & Screening
        • Drug Discovery
        • Drug Discovery & Development
        • Drug Optimization
        • Drug Repurposing
        • Safety
        • Therapeutics
        • Understanding Diseases

        By Type

        • Deep Learning
        • Disease Diagnosis
        • Disease Progression, Staging & Prognosis
        • Disease Screening
        • Other Machine Learning Types
        • Post Treatment Surveillance & Follow-Up
        • Reinforcement Learning
        • Risk Assessment & Patient Stratification
        • Supervised Learning
        • Therapy Monitoring
        • Therapy Selection & Planning
        • Unsupervised Learning

        By Therapeutic Area

        • Cardiology
        • Hematology
        • Infectious Diseases
        • Neurology
        • Oncology
        • Other Therapeutic Area
        • Other Therapeutic Areas
        • Rare Disease
        • Rare Diseases

        By Component

        • Services
        • Software

        By Tool

        • Computer Vision
        • Context Aware Processing
        • Context-Aware Processing
        • Context-Aware Processing & Computing
        • Image Analysis
        • Machine Learning
        • Natural Language Processing
        • Nlp
        • Other Tools

        By Deployment

        • Cloud-Based
        • Cloud-Based Model
        • Hybrid
        • Hybrid Model
        • On-Premise
        • On-Premise Model

        By End User

        • Healthcare Providers
        • Medical Device/Equipment Companies
        • Other End Users
        • Pharmaceutical & Biotechnology Companies
        • Research Centers, Academic Institutes & Government Organizations
        • Research Centers, Academic Institutes, & Government Organizations

        By Deployment 2022-2030

        • Cloud Based
        • Cloud-Based
        • Hybrid
        • On-Premise

        UK: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER, 2022–2030

        Segment202220232024202520262027202820292030CAGR (%)
        HEALTHCARE PROVIDERS10.4313.9918.7625.1433.6745.160.3880.8108.1133.9
        MEDICAL DEVICE/EQUIPMENT COMPANIES6.658.8911.8815.8821.2228.3337.8250.4767.3233.5
        OTHER END USERS3.564.726.248.2610.9314.4619.1125.2633.3732.2
        PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES8.0210.5413.8518.1823.8631.3141.0653.8470.5631.2
        RESEARCH CENTERS, ACADEMIC INSTITUTES, & GOVERNMENT ORGANIZATIONS4.295.67.299.512.3716.120.9527.2435.4130.1
        TOTAL32.9543.7358.0276.96102.06135.3179.32237.61314.7632.6

        Target Audience

        • NHS Trust Leadership : Hospital executives and digital health directors need market intelligence to justify AI precision medicine investments, understand peer adoption patterns, and align procurement decisions with national health priorities and funding availability.
        • Healthcare Technology Vendors : Software and AI solution providers require UK-specific market data to develop localized offerings, understand NHS requirements, navigate regulatory pathways, and identify partnership opportunities with healthcare institutions.
        • Private Healthcare Operators : Private hospital networks and specialist clinics need competitive insights and market sizing data to evaluate precision medicine AI investments, differentiate services, and capture growing demand for personalized treatment options.
        • Medical Device and Pharma Companies : Pharmaceutical and diagnostics firms need precision medicine market trends to inform companion diagnostic development, clinical trial design, and commercialization strategies aligned with UK healthcare delivery models.
        • Healthcare Investors and Consultants : Investment firms and management consultants require detailed UK market analysis to identify growth opportunities, assess portfolio companies, and advise clients on market entry strategies and competitive positioning.

        Reasons to Buy this Report

        • NHS Market Opportunity : Gain insights into NHS procurement strategies, trust-level adoption patterns, and integration requirements to position solutions for the largest healthcare buyer in the UK market with standardized procurement processes.
        • Competitive Landscape Intelligence : Understand UK-specific competitive dynamics, identify key players in the precision medicine AI space, and benchmark your offerings against established and emerging competitors operating within the NHS and private healthcare sectors.
        • Regulatory Pathway Clarity : Access detailed analysis of MHRA approval processes, NICE evaluation criteria, and UK-specific compliance requirements to accelerate market entry and reduce regulatory uncertainty for AI precision medicine solutions.
        • Investment and Funding Trends : Identify funding sources, venture capital activity, and government grants specific to UK precision medicine AI initiatives to inform partnership strategies and investment decisions in the growing market.
        • Clinical Implementation Insights : Understand real-world deployment challenges, clinical workflow integration requirements, and adoption barriers across NHS trusts and private providers to optimize product development and go-to-market strategies.

        Frequently asked questions

        What is the current size of the UK AI in Precision Medicine market?

        The UK AI in Precision Medicine market was valued at $3.45 million in 2024 and is expected to reach $17.54 million by 2029.

        What is the projected growth rate for the UK market?

        The UK market is projected to grow at a compound annual growth rate (CAGR) of 24.2% from 2024 to 2029.

        Which healthcare sectors in the UK are driving AI precision medicine adoption?

        The UK's oncology, cardiology, and rare disease management sectors are primary drivers of AI precision medicine adoption, supported by NHS digitalization efforts.

        How is the UK regulatory environment supporting AI in precision medicine?

        The UK's regulatory framework, including MHRA oversight and NHS integration strategies, provides a supportive environment for AI precision medicine innovation and deployment.

        What role does the UK's life sciences sector play in market growth?

        The UK's established life sciences ecosystem, academic research institutions, and partnerships between universities and healthcare technology companies are key drivers of AI precision medicine market expansion.

        RESEARCH METHODOLOGY

        The study involved significant activities to estimate the current size of the AI in precision medicine market. Exhaustive secondary research was done to collect information on the AI in precision medicine market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the AI in precision medicine market.

        Secondary Research

        This research study involved the wide use of secondary sources, directories, and databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva; white papers, annual reports, and companies’ house documents; investor presentations; and the SEC filings of companies. The market for the companies offering AI in precision medicine solutions is arrived at by secondary data available through paid and unpaid sources, analyzing the product portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases.

        Various secondary sources were referred to in the secondary research process to identify and collect information related to the study. These sources included annual reports, press releases, investor presentations of AI in precision medicine vendors, forums, certified publications, and whitepapers. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and technology-oriented perspectives.

        Primary Research

        In the primary research process, various primary sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side included industry experts, such as Chief Executive Officers (CEOs), Vice Presidents (VPs), marketing directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the AI in precision medicine market.

        After the complete market engineering (calculations for market statistics, market breakdown, market size estimations, market forecasting, and data triangulation), extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. Primary research was also undertaken to identify the segmentation types, industry trends, competitive landscape of AI in precision medicine solutions offered by various market players, and key market dynamics, such as drivers, restraints, opportunities, challenges, industry trends, and key player strategies.

        In the complete market engineering process, the top-down and bottom-up approaches and several data triangulation methods were extensively used to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.

        Breakdown of Primary Participants:

        AI in Precision Medicine Market

        Note 1: Others include sales managers, marketing managers, and product managers.

        Note 2: Tiers of companies are defined based on their total revenues in 2023. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.

        To know about the assumptions considered for the study, download the pdf brochure

        Market Size Estimation

        Both top-down and bottom-up approaches were used to estimate and validate the total size of the AI in precision medicine market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

        • The key players in the industry and markets have been identified through extensive secondary research.
        • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
        • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
        AI in Precision Medicine Market

        Data Triangulation

        After arriving at the overall market size using the market size estimation processes explained above, the market was split into several segments and subsegments. The data triangulation and market breakup procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment. The data was triangulated by studying various factors and trends from both the demand and supply sides.

        Market Definition

        The AI in precision medicine market utilises AI technologies such as machine learning and natural language processing to analyse complicated biological and clinical data in order to provide possibly personalised healthcare solutions. It promotes applications such as drug discovery, diagnostics, predictive analytics, and tailored treatment plans by integrating genomics, proteomics, and real-world data using AI capabilities with the goal of improving patient outcomes and accelerating innovation benefits for stakeholders ranging from pharmaceutical companies and healthcare providers to researchers.

        Stakeholders

        • Transfection products manufacturing companies
        • Pharmaceutical & Biopharmaceutical Companies
        • Chemical Companies
        • Biopharmaceutical Companies
        • Contract Research Organizations (CROs)
        • Contract Development and Manufacturing Organizations (CDMOs)
        • Research Institutes and Universities 
        • Venture Capitalists & Investors
        • Government Associations

        Report Objectives

        • To define, describe, and forecast the AI in precision medicine market based on application, therapeutic area, component, tools, deployment, end user, and region.
        • To provide detailed information about the major factors (drivers, opportunities, restraints, and challenges) influencing the growth of the market
        • To analyze opportunities for stakeholders by identifying the high-growth segments of the market
        • To forecast the size of the market segments with respect to five main regions: North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America
        • To analyze subsegments of the market with respect to individual growth trends, prospects, and contributions to the overall market
        • To profile the key players and comprehensively analyze their market sizes and core competencies.
        • To track and analyze competitive developments such as acquisitions, collaborations, agreements, mergers, product launches & updates, partnerships, expansions, and other recent developments in the market globally.

        Get the Full AI in Precision Medicine Market Report

        Full forecast, segment splits, and company analysis for all AI in Precision Medicine Market.

        Need a Tailored Report?

        Customize this report to your needs

        Get 10% FREE Customization

        Customize This Report
        Fact checked
        DMCA.com Protection Status